This American Depository Receipt (ADR) represents shares in Addex Therapeutics, a pharmaceutical company developing new drugs to treat neurological disorders. It focuses on creating small molecule drugs that can be taken orally and work by binding to specific proteins in the brain, modulating their activity to improve brain function.